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Summary
 
Contact sensitivity (CS) responses to reactive hapten Ag, such as picryl chloride (PCl) or ox-
azolone (OX), are classical examples of T cell–mediated immune responses in vivo that are
clearly subject to multifaceted regulation. There is abundant evidence that downregulation of
CS may be mediated by T cells exposed to high doses of Ag. This is termed high dose Ag tol-
erance. To clarify the T cell types that effect CS responses and mediate their downregulation,
we have undertaken studies of CS in mice congenitally deficient in specific subsets of lympho-
cytes. The first such studies, using 
 
ab
 
 T cell–deficient (TCR
 
a
 
2
 
/
 
2
 
) mice, are presented here.
The results clearly show that TCR
 
a
 
2
 
/
 
2
 
 mice cannot mount CS, implicating 
 
ab
 
 T cells as the
critical CS-effector cells. However, TCR
 
a
 
2
 
/
 
2
 
 mice can, after high dose tolerance, downregu-
late 
 
a
 
1
 
/
 
1
 
 CS-effector T cells adoptively transferred into them. By mixing ex vivo and then
adoptive cell transfers in vivo, the active downregulatory cells in tolerized 
 
a
 
2
 
/
 
2
 
 mice are
shown to include 
 
gd
 
 TCR
 
1
 
 cells that also can downregulate interferon-
 
g
 
 production by the
targeted CS-effector cells in vitro. Downregulation by 
 
gd
 
 cells showed specificity for hapten,
but was not restricted by the MHC. Together, these findings establish that 
 
gd
 
 T cells cannot
fulfill CS-effector functions performed by 
 
ab
 
 T cells, but may fulfill an Ag-specific downregu-
latory role that may be directly comparable to reports of Ag-specific downregulation of IgE an-
tibody responses by 
 
gd
 
 T cells. Comparisons are likewise considered with downregulation by
 
gd
 
 T cells occurring in immune responses to pathogens, tumors, and allografts, and in systemic
autoimmunity.
 
C
 
utaneous contact sensitivity (CS)
 
1
 
 responses to contact
sensitizing hapten Ag such as picryl chloride (PCl) and
oxazolone (OX) are classical manifestations of T cell–medi-
ated immunity in vivo. In previously sensitized hosts, CS
and the related delayed-type hypersensitivity (DTH) reac-
tion, are manifest as macroscopically measurable inflamma-
tion (skin swelling) that peaks at 24–48 h after topical cuta-
neous Ag challenge (1).
It appears that early after challenge with hapten, local tis-
sue mast cells (2, 3) and blood platelets (4) are induced to
release the vasoactive amine serotonin (2–6) that facilitates
local extravasation and subsequent migration and activation
of Ag-specific CS-effector lymphocytes. Available data
strongly suggest, but do not prove, that the responding late-
acting lymphocytes are exclusively MHC class II–restricted,
 
ab
 
 TCR
 
1
 
, CS-effector T cells (7, 8), which customarily
make Th1-type effector cytokines, such as IFN-
 
g
 
 (9–11).
By contrast to the conventional CS-effector response,
which is induced by immunization via skin painting with
reactive hapten Ag, mice respond to high intravenous doses
of soluble hapten Ag by developing tolerance. This high
dose Ag tolerance is of particular significance with regard
to the capacity of individuals that become tolerant toward
contact hapten allergens, and may also underlie aspects of
tolerance to self Ag. Numerous studies have demonstrated
 
1
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TMB, tetramethylbenzidine; TNBSA, Trinitro-benzene sulfonic acid.
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a
 
2
 
/
 
2
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that high dose tolerance can be associated with the devel-
opment of regulatory T cells that limit the response of CS-
effector T cells (12–17). In this regard, it is unclear whether
or not such CS-downregulatory T cells are exclusively 
 
ab
 
T cells, or whether they may include 
 
gd
 
 T cells.
An assay commonly used to demonstrate high dose down-
regulation of CS, is the mixing together in vitro of spleen
cells from mice tolerized intravenously with high doses of
Ag, together with CS-effector cells from contact sensitized
mice. Thereafter, the mixed regulatory and CS-effector cells
are adoptively transferred to naive recipients, and a subse-
quent measurement is made of the transferred CS-effector
response in the recipients. The studies reported in this
manuscript use this mixing assay and other established as-
says, along with use of TCR-deficient 
 
a
 
2
 
/
 
2
 
 mice, to assess
the cells responsible for CS elicitation and for CS downreg-
ulation, respectively. The studies show that 
 
gd
 
 T cells can-
not substitute for 
 
ab
 
 T cells as effectors of CS elicitation, but
that 
 
gd
 
 T cells can medite downregulation of both 
 
ab
 
 CS ef-
fectors in vivo and IFN-
 
g
 
 production by these CS effectors
in vitro. The studies are particularly pertinent given the re-
ported capacity of 
 
gd
 
 T cells to negatively regulate 
 
ab
 
 T
cell–driven responses in allergic (18, 19) and other immune
responses.
 
Materials and Methods
 
Mice.
 
5–7-wk-old 129/J (H2
 
b
 
), BDF
 
1
 
 (H2
 
b
 
 
 
3
 
 
 
d
 
), C57Bl/6
(H2
 
b
 
), BALB/c (H2
 
d
 
), and CBA/J (H2
 
k
 
) mice were obtained
from Jackson Labs (Bar Harbor, ME). TCR
 
a
 
2
 
/
 
2
 
 and TCR
 
a
 
1
 
/
 
2
 
mice (20–22) with different but defined MHC backgrounds that
included H2
 
b
 
, H2
 
d
 
, and H2
 
b
 
1
 
d
 
, were supplied locally. All mice
were maintained in microisolator cages, and changed in a laminar
flow hood. MHC haplotypes were determined by FACS
 
Ò
 
 with anti-
MHC class I
 
b
 
 (PE-conjugated), and class I
 
d
 
 (FITC-conjugated)
mAb (PharMingen, San Diego, CA).
 
Reagents.
 
Picryl chloride TNP chloride (PCl) obtained from
Chemica Alta (Edmonton, Alberta, Canada) was recrystallized
from methanol/H
 
2
 
O, and protected from light and humidity.
Trinitro-benzene sulfonic acid (TNBSA) (Eastman Fine Chemi-
cals, Rochester, NY); oxazolone (4-ethoxymethylene-2-pheny-
loxazolone) (OX) (British Drug Houses via Gallard-Schlesinger
Inds. Inc., Carle Place, NY); and anti–hamster IgG antibody-
coated magnetic beads (1 
 
m
 
m iron magnetic particles; Advanced
Magnetics, Inc., Cambridge, MA) were obtained from the manu-
facturers. Anti-TCR 
 
gd
 
 mAb (clone UC7-135D5, hamster IgG),
was obtained from Dr. J. Bluestone (University of Chicago, Chi-
cago, IL; 23). Low-tox rabbit complement C was obtained from
Pel-Freeze Biologicals (Brown Deer, WI).
 
Active Immunization.
 
Mice were actively sensitized by topical
application of 0.15 ml of 5% PCl or 3% OX in 1:3 acetone–etha-
nol mixture, to the shaved abdomen, chest, and hind feet on day
0. 4 d later, zero time ear thickness was measured with an engi-
neer’s micrometer (Mitutoyo Mfg. Co., Tokyo, Japan) before lo-
cal ear skin challenge via topical application to both sides of both
ears of one drop of 0.8% PCl or OX solution in olive oil (for 129/J,
BALB/c, TCR
 
a
 
1
 
/
 
2
 
 and 
 
a
 
2
 
/
 
2
 
), or 1% PCl to less reactive BDF
 
1
 
or C57Bl/6. The subsequent optimal increase in ear thickness
was measured at 24 h, and occasionally 48 h, after challenge as re-
ported (1–8), and expressed in units of 0.01 mm 
 
6
 
 SE. In all ex-
periments, a group of nonimmune control animals was also chal-
lenged on the ears with 0.8% PCl or OX, and the resulting
background increase in ear thickness (
 
z
 
2 U at 24 h) was sub-
tracted from responses of experimental groups to yield net ear
swelling responses, shown in the figures.
 
Induction of High Ag Dose Tolerance.
 
For induction of TNP–
specific high dose tolerance, mice received two intravenous in-
jections of 3 mg TNBSA (1% TNBSA in distilled H
 
2
 
0, readjusted
to pH 7.2 with 1 M NaOH) in 0.3 ml on days 0 and 3. On day 7,
spleens from these TNBSA-injected mice were harvested as a
source of putative regulatory cells. Alternatively, mice were toler-
ized by intravenous injection of TNP-conjugated syngeneic
spleen cells.
To induce OX-specific tolerance, mice were injected intrave-
nously once with 0.3 ml of 10% OX-conjugated mouse red
blood cells (MRBC), or with OX-conjugated spleen cells (5 
 
3
 
10
 
7
 
) on days 0 and 3. The MRBC or spleen cells were labeled
with OX as described previously (12). Briefly, 1 ml of packed
MRBC was resuspended in 10 ml of DPBS (calcium- and mag-
nesium-free PBS) and mixed for 30 min with freshly prepared 20
ml aqueous OX solution (containing 20 mg OX). The OX-
MRBC were then washed twice with PBS containing 5% FCS,
and before use, the peletted OX-MRBC were resuspended to
10% in PBS. Spleens from mice injected intravenously with OX-
MRBC, or with OX spleen cells, were harvested on d 7 as a
source of OX-specific regulatory cells.
 
Adoptive Cell Transfer of CS Responses and Cell Mixing Assay.
 
Donors of CS-immune effector cells were contact sensitized with
5% PCl or 3% OX on days 0 and 3. Immune lymph node and
spleen cells were harvested on day 7 and 7 
 
3
 
 10
 
7
 
 were injected
intravenously into normal syngeneic recipients. Immediately after
transfer, recipients were challenged on the ears with 0.8% PCl or
OX in olive oil. The increase in ear swelling was determined 24 h,
and sometimes 48 h later. It was compared to actively sensitized
positive controls and to negative controls that were simply chal-
lenged on the ears with 0.8% PCl or OX.
For the cell mixing assay, 5–7 
 
3
 
 10
 
7
 
 CS-effector immune
lymph node and spleen cells from PCl or OX contact sensitized
 
a
 
1
 
/
 
1
 
 donors were incubated for 30 min at 37
 
8
 
C with 5 
 
3
 
 10
 
7
 
regulatory spleen cells from mice intravenously tolerized with
TNBSA or with OX-MRBC. Regulatory spleen cells were from
tolerized 
 
a
 
2
 
/
 
2
 
 mice, or control 
 
a
 
1
 
/
 
1
 
 129/J, C57Bl/6, BALB/c,
or BDF
 
1
 
 mice. Positive controls were immune CS-effector cells
incubated without regulatory cells. After incubation, washed
mixed cells from each group were transferred intravenously, and
recipients were tested for CS responses by ear challenge with top-
ical application of 0.8% PCl or OX, within 30 min immediately
after transfer.
 
Transfer into Tolerized Mice to Confirm Active Tolerance and Ag-
specificity.
 
To test tolerance and Ag specificity of downregula-
tory cells in another system, 
 
a
 
2
 
/
 
2
 
 mice were tolerized with a
high dose of TNBSA or with OX-MRBC intravenously on days
0 and 3 before serving as cell transfer recipients. Then on day 7,
nontolerized control or TNP- or OX- tolerized 
 
a
 
2
 
/
 
2
 
 mice re-
ceived 7 
 
3
 
 107 CS-effector cells from normal TCRa1/1 mice
(BALB/c) that were Ag homologous, or were of unrelated Ag
specificity (TNP versus OX). a2/2 recipient mice were then
challenged immediately on the ears with homologous hapten
(TNP or OX), and ear tested for 24 h ear swelling.
Immuno-magnetic Bead Cell Fractionation. Spleen cells (1.5 3
108) from four TNBSA-tolerized a1/1 129/J, or a2/2 donor2131 Szczepanik et al.
mice were incubated in 20 ml UC7 hamster anti-TCR gd mAb
(12 mg/ml) hybridoma supernatant for 60 min on ice. After mAb
coating, cells were washed three times with PBS 1 2% FCS, and
resuspended in 40 ml PBS 1 2% FCS containing goat anti–ham-
ster Ig–coated paramagnetic beads at 5–10 beads per target cell.
The cells were then incubated in a flat vertical 50-ml flask for 30
min on ice, after which a magnet (Advanced Magnetics Inc.,
Cambridge, MA) was applied to one side of the flask. 10 min
later, magnetic bead nonadherent cells were recovered, and then the
magnetic bead adherent cells were recovered. Nonseparated reg-
ulatory cells were used in experiments shown in Figs. 3, 5, and 6 b.
Recoveries of gd cells were as follows. For 129/J TNBSA-tol-
erized donors, we harvested 15 3 107 separated spleen cells from
three donors, obtaining z106 anti-gd magnetic bead positive cells
that were 60% gd1 by FACSÒ. Thus, there were z1.6 3 105 gd
cells transferred to each of four recipients, while there were 10 3
105 gd cells in the starting spleen of one donor mouse. For a2/2
TNBSA-tolerized donors, we harvested 20 3 107 spleen cells
from three donors, obtaining 3.4 3 106 anti-gd bead positive to-
tal cells that were on average 80% gd1 by FACSÒ, thus allowing
for 7 3 105 gd-enriched cells transferred to each of four recipi-
ents. FACSÒ analysis of the anti-gd immunobead separated sub-
populations was presented elsewhere (24), in which we reported
that the percentage of gd cells adhering to the anti-gd beads can
vary between 55–95% of the total adherent cells; the rest are not
specifically bound, and on assay did not have biologic activity.
Also, we noted that unavoidable splenic macrophage phagocyto-
sis of some mAb-coated gd cells that were attached to beads,
probably contributed to variability in gd T cell recoveries.
Mixing of CS-effector Cells and Magnetic Bead-enriched Regulatory
Cells. Immune CS-effector cells (7 3 107) were incubated with
5 3 107 unseparated regulatory T cells, with an equivalent num-
ber of separated magnetic bead positive gd cells, or with an
equivalent number of magnetic bead nonadherent gd2 cells (i.e.,
ab TCR1-remaining cells) originating from either tolerized 129/J
a1/1 mice or TCRa2/2 mice for 30 min at 378C. The washed
effector and regulatory cell mixture was then injected intraperito-
neally into naive 129/J recipients that were tested for CS re-
sponses by challenging ears with 0.8% PCl or OX in olive oil the
next day. Recipients were then measured for ear swelling 24 h af-
ter Ag challenge to the ears.
In Vitro Culture of CS-effector Cells and Hapten-conjugated APC
for Elaboration of IFN-g, and Regulation by Tolerized Cells. A sin-
gle cell suspension of just CS-effector lymph node cells was ob-
tained aseptically from PCl contact sensitized mice. Suspensions
of regulatory cells were from spleen cells of mice that were in-
jected with TNBSA or OX-MRBC intravenously on days 0 and 3,
or from control nonimmune mice. In some experiments, spleen
cells from TNBSA-tolerized mice, or nonimmune controls, were
incubated with 1 mg biotinylated anti-gd TCR (GL3; PharMin-
gen) per 106 cells at 2 3 107 cells/ml for 20 min on ice. Then, 10 ml
of streptavidin-conjugated magnetic microbeads (Miltenyi, Sunny-
vale, CA and BioTek Instrs. Inc., Sunnyvale, CA) per 107 cells
were added and incubated for 15 min on ice. After washing, this
cell and bead suspension was applied to a MiniMACS magnetic
separation column (Miltenyi). After recovering of nonadherent
gd-depleted cells and washing the column, gd-enriched adherent
cells were eluted. Equivalent numbers of gd-enriched, or gd-
depleted cells were added in vitro as regulatory cells, to the CS-
effector cells (1:1; 2 3 105/well), and then were added together
for 72 h to mitomycin C–treated TNP- or OX-conjugated nor-
mal spleen cells as APC (2 3 105) in 0.2 ml of RPMI 1640 con-
taining 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM l-glu-
tamine, 25 mM Hepes, 5 3 1025 M/2-mercaptoethanol, and
10% fetal calf serum. At 48 h, culture supernatants were collected
for IFN-g quantitation.
ELISA Quantitation of IFN-g in Culture Supernatants. Quan-
titative sandwich ELISA for IFN-g was performed with two dif-
ferent mAb specific for mouse IFN-g (clones R4-6A2 and
XMG1.2; Pharmingen). 1 mg/ml of capture mAb to IFN-g in
0.1 M Na2CO3, pH 8.3, was briefly coated onto 96-well microtrays
(Corning Glass Incorporated, Corning, NY) overnight at 48C. Af-
ter blocking with 3% dry milk in PBS, samples and standard re-
combinant mouse IFN-g (Genzyme Corp., Cambridge, MA)
were applied to the wells and incubated overnight at 48C. Then,
0.5 mg/ml of biotinylated separate mAb to IFN-g was applied for
45 min at 258C, followed by incubation with 1:3,000 dilution of
horseradish peroxidase–conjugated streptavidin (Vector Labs.,
Inc., Burlingame, CA), for 30 min at 258C. TMB (tetramethyl-
benzidine) microwell peroxidase substrate, and TMB one com-
ponent stop solution (Kirkegaard & Perry Laboratories, Inc.,
Gaithersburg, MD) were used for reaction development and were
read at OD 405.
Statistics. Double-tailed Student’s t test was used to assess the
significance of differences between groups, with P ,0.05 taken as
a minimum level of significance.
Results
TCRa2/2 Mice Have No 24 h CS Responses. CS responses
in contact sensitized TCRa2/2 mice and control 129/J mice
were compared by sensitizing (via abdominal skin painting)
with concentrated PCl (5%), followed 4 d later by topical
challenge with dilute PCl (0.8%) applied to the ears, and
subsequent measurement of ear swelling 24 h later. It was
Figure 1. Actively sensitized TCRa knock out mice (a2/2) have no
classical late 24 h cutaneous CS responses, but can serve as adoptive cell
transfer recipients. TCRa1/1 129/J (group A) or TCRa2/2 (group B)
mice, were contact sensitized with 0.15 ml of 5% PCl skin painting. 4 d
later, animals were challenged on the ears with 0.8% PCl, and CS re-
sponses were determined 24 h later by measuring increases in ear thick-
ness with an engineer’s micrometer. Results were expressed as U 3 0.01
mm 6 SE. Background ear swelling in PCl challenged controls that were
not sensitized, were subtracted from experimental groups to give net ear
swelling, as is shown. BDF1 (group C) a1/1 immune cells from PCl con-
tact sensitized donors were transferred intravenously to BDF1 recipients,
or to TCRa2/2 H2b recipients (group D) that were ear challenged simi-
larly, and then, 24 h ear swelling responses were determined.2132 gd1 Inhibitory Cells in TCRa2/2 Mice
found that ab T cell–bearing 129/J mice developed a clas-
sical 24 h ear swelling response (Fig. 1, group A), whereas
TCRa2/2 mice did not (Fig 1, group B).
When a2/2 mice were used as recipients of ab1 cells
from MHC-matched, immunized ab T cell–sufficient BDF1
mice, they could mount CS upon ear challenge with hap-
ten (Fig. 1, group D), similar to normal mice (Fig. 1, group
C). This demonstrated that the vascular and cellular envi-
ronment for eliciting CS was normal in TCRa2/2 knock-
out mice. The finding that the 24 h component of CS can-
not be elicited in actively sensitized TCRa2/2 mice is
consistent with other studies indicating that the active CS-
effector cell type is TCRab1 (7, 8, 24–26).
High Dose Ag Tolerance of TCRa2/2 mice Induces Regulatory
Spleen Cells that Downregulate CS. Because TCRa2/2 mice
do not mount CS responses, it is impossible to determine
directly whether high dose Ag tolerization of such mice in-
duces downregulatory cells. Instead, CS-effector cells (7 3
107) from contact-sensitized 129/J mice were mixed and
incubated for 30 min at 378C with 5 3 107 spleen cells
from a2/2 mice, that were harvested on d 7 after two in-
travenous injections of tolerogenic TNBSA. Analogous
TNBSA-tolerized cells were derived from TNBSA-treated
MHC haplotype-matched TCRa1/2 mice, or TCRa1/1
(129/J) mice. The cells were then transferred back to hap-
lotype-matched recipient mice that were challenged with
hapten.
Fig. 2 shows that upon transfer back to recipient mice,
CS-effector cells elicit a 24 h response that can be signifi-
cantly reduced by preincubation of the effector cells with
cells from tolerized TCRa1/1 mice (Fig. 2, group B),
TCRa1/2 mice (Fig. 2, group C), or TCRa2/2 mice (Fig.
2, group D). Essentially the same results were obtained
when effector cells from sensitized BDF1 mice were mixed
with cells from either TNBSA-tolerized BDF1 mice or
TNBSA-tolerized TCRa2/2 mice (Fig. 2, groups E–G).
A prediction that follows from the data shown in Fig. 2
(groups A–G) is that TCRa2/2 mice will not support the
actions of adoptively transferred TCRa1/1 CS-effector
cells if the recipient a2/2 mice are subject to high dose Ag
tolerance beforehand. The data in Fig. 2, groups H and I
confirm this prediction. This result is important in that it
rules out that the detection of TCRa2/2 downregulatory
cells in adoptive transfer experiments (Fig. 2, groups D and G)
was artefactual, due to manipulation of the cells in vitro
and their subsequent transfer. Furthermore, induction of
high dose tolerance by TNBSA in TCRa2/2 mice was re-
producibly demonstrated using transfers from individual
TCRa2 mice (data not shown), indicating the generality
of the findings.
Expression of gd TCR on CS-regulatory Cells from Tolerized
TCRa2/2 Mice. To determine the phenotype of CS-reg-
ulatory cells induced by high Ag dose tolerance, spleno-
cytes from TNBSA-tolerized mice were fractionated by use
of anti-TCR gd mAb-coated magnetic beads. gd1, gd2, or
unfractionated tolerized cells were then mixed for 30 min
at 378C with lymph node and spleen CS–effector cells (7 3
107) from contact immunized, haplotype–matched mice,
and the mixture transferred to recipients that were subse-
quently assayed for CS responses by ear challenge. In these
experiments, anti-gd bead adherent cells ranged from 55 to
95% gd TCR1 when reanalyzed by FACSÒ (see Materials
and Methods). Thus, we estimate that >106 gd cells were
adoptively transferred into each recipient when unsepa-
rated TCRa2/2 cells were used, and about >7 3 105 gd
cells were transferred when magnetic bead gd–enriched
cells were used.
The data in experiments 1 and 2 of Fig. 3 show that
while the cells from TNBSA-treated a1/1 129/J mice that
are responsible for downregulating CS effectors are exclu-
sively TCR gd2 (group D), the most potent regulatory cell
fraction from tolerized TCRa2/2 mice scored as TCR gd1
(Fig. 3, group F). Similar results were obtained in experi-
ment three, in which cells from H2d TCRa2/2 mice were
Figure 2. High dose Ag tolerance of TCRa2/2 mice induces cells that
downregulate CS and generate an inhibitory environment. As an assay for
generation of downregulatory cells, CS-effector cells (7 3 107) from PCl
contact sensitized 129/J mice (groups A–D) were incubated for 30 min at
378C, alone (group A, positive controls), or with 5 3 107 putative regula-
tory cells induced by two intravenous injections of TNBSA in TCRa1/1
129/J (group B), TCRa1/2 (group C), or TCRa2/2 (group D) mice.
The cell mixture was then washed and transferred intravenously into na-
ive syngeneic 129/J recipients that immediately were challenged on the
ears with 0.8% PCl. Groups B–D were significantly different (P ,0.001)
from control group A. In groups E–I, from a pooled separate experiment,
TCRa1/1 BDF1 mice or their TCRa2/2 H2b,d counterparts were used.
BDF1 are poorly CS-reactive and thus were skin sensitized with PCl
twice (days 0 and 3). On d 7, immune CS-effector lymph node and
spleen cells (7 3 107), from these mice were injected intravenously into
normal BDF1 mice (groups E–G), or into TCRa2/2 recipients (groups H
and  I). Tolerized downregulatory cells were induced in BDF1 or
TCRa2/2 mice by two intravenous injections of 5 3 107 TNP-conju-
gated TCRa2/2 spleen cells on days 0 and 3. Spleens from these tolerized
mice served as a source of downregulatory cells respectively in groups F
and G, in which 3.5 3 107 tolerized cells were mixed and incubated with
BDF1 PCl-immune cells (7 3 107), before being injected intravenously
together into the recipients. In group H, recipient TCRa2/2 animals
were tolerized via prior intravenous injection of TNP-conjugated spleen
cells, i.e., they were tolerized by a procedure similar to inducing regula-
tory cells used in the mixing and adoptive transfer experiments (groups
E–G). Statistical significance: group E vs F, I and H, P ,0.005. Each
group consisted of three animals. In group I, BDF1 CS-immune cells
were transferred successfully into untreated TCRa2/2 mice.2133 Szczepanik et al.
compared with cells from H2d BALB/c mice for their re-
sponse to high dose Ag tolerance. As before, when measur-
ing the capacity of tolerized cells to downregulate a CS-
effector response to PCl, the TCR gd1 fraction from
TCRa2/2 mice, but not from a1/1 BALB/c mice, was
again active (experiment 3, group C). Conversely, the ac-
tive fraction from normal a2/2 mice was TCR ad1 (group
D), and the TCR gd2 fraction from TCRa2/2 mice
(group  E) contained negligible residual activity.
gd T Cell–mediated Regulatory Activity Shows Antigen Spec-
ificity. The discovery that gd T cells in TCRa2/2 mice
can mediate downregulation of CS effector cells prompted
an investigation of Ag specificity, since gd T cells and ab
cells appear to have a different set of Ag specificities. To
test this, cells from TCRa2/2 mice tolerized with high
doses of OX or TNP, were mixed with CS-effector cells
from TCRa1/1 mice sensitized with PCl or OX, and
compared in their capacities to downregulate the 24 h CS
response after transfer back to recipient mice. Data pre-
sented in Fig. 4 a show no capacity of cells from OX-toler-
ized TCRa2/2 mice to influence the CS response to TNP
(group B), whereas TNP responses were inhibited signifi-
cantly after mixing effector cells with cells from TNP-tol-
erized TCRa2/2 mice (Fig. 4 a, group C). Data in Fig. 4 a,
groups D–F demonstrate that reciprocal Ag specificity was
likewise apparent (i.e., cells from OX-tolerized TCRa2/2
mice downregulated effector cells from OX-sensitized mice,
but not a1/1 TNP–immune cells) (group E versus F).
To confirm the above findings we tested Ag-specificity
in tolerized a2/2 mice by attempting to transfer a1/1
CS-effector cells into these recipients. a2/2 mice were tol-
erized with a high dose of TNBSA or OX-MRBC intra-
venously before cell transfer. Then, on day 7, control (non-
tolerized) or TNP or OX-tolerized a2/2 mice received 7 3
107 TNP or OX immune cells from normal a1/1 (BALB/c)
mice. The data presented in Fig. 4 b show there was no
ability to adoptively transfer immunity into TNP tolerized
a2/2 mice with TNP-specific CS-effector cells (group B),
while TNP-immune CS-effector cells transferred normal
CS responses into OX-tolerized a2/2 recipients (group C).
Similar data were obtained when OX-specific immune
cells were transferred (group D versus F). Thus, total inhi-
bition of adoptive cell transfer was obtained when OX-
specific immune CS-effector cells were transferred to OX-
tolerized a2/2 mice (Fig. 4 b, group E), whereas OX CS
was successfully transferred to TNP-tolerized a2/2 mice
(Fig. 4 b, group F). Thus, this system that did not involve
cell harvest, cell mixing, nor cell transfer, confirmed the
presence of active Ag-specific downregulation in high
dose–tolerized  a2/2 mice.
gd T Cell–mediated Regulatory Activity is MHC Unrestricted.
To determine possible MHC restriction of gd downregula-
tory T cells, magnetic bead-enriched gd TCR1 cells from
TNBSA-tolerized a2/2 mice were incubated with 7 3
107 PCl-immune CS-effector cells from MHC-compatible
(129/J, H2b), or -incompatible (CBA/J, H2k) mice, for 30
min at 378C, followed by subsequent transfer to recipients
syngeneic with the CS-effector cells. The recipient mice
were challenged immediately (before any significant host
response to the allogeneic gd graft could develop), and ear
swelling responses determined. The results in Fig. 5 show
that  gd1 cells from TNBSA-tolerized TCRa2/2 mice
downregulated CS-effector responses of allogeneic CBA/J
H2k CS-effector cells (group D), as effectively as the regu-
lation of H2-matched CS-effector cells (group B).
Phenotype and dose–response Activity of CS-regulatory gd T
Cells. To establish the phenotype of gd T cells capable of
inhibiting CS-effector responses, spleen cells from TN-
BSA-tolerized a2/2 mice were treated with anti-CD4 or
anti-CD8 mAb or PBS, and then rabbit complement 1:75.
Figure 3. gd T cells are responsible for
CS downregulatory activity of high dose Ag
tolerized TCRa2/2 mice. In experiments 1
and 2, spleen cells (1.5 3 108) from TNBSA
intravenous tolerized 129/J (group B), or
TCRa2/2 animals (group E), were sepa-
rated into gd TCR1 (groups C and F), and
gd TCR2 (groups D and G) subpopulations
by anti-gd TCR mAb treatment in solu-
tion, and then incubation with anti–hamster
Ig-coated para magnetic beads, and subse-
quently separated in vitro by exposure to a
magnet. In experiment 3, similar cell frac-
tionation used a1/1 BALB/c and their a2/2
H2d counterparts. Immune CS-effector cells
(7  3 107) were incubated for 30 min at
378C with downregulatory, separated, mag-
netic bead positive cells (gd TCR1) (groups
C and F), or magnetic bead negative (gd
TCR2) cells (groups D and G), that were
from either TNBSA-tolerized 129/J or
BALB/c mice (groups C, D), or TNBSA-
tolerized TCRa2/2 animals (groups F, G). Cell mixtures were then washed and injected intraperitoneally into naive recipients. As a positive control,
CS-effector cells incubated without regulatory cells were transferred intraperitoneally (group A). The next day, animals were challenged on the ears with
0.8% PCl in olive oil and the increment in ear swelling was determined 24 h later. Statistical significance: group A vs B and D, P ,0.01; group A vs
group E, P ,0.05; and group A vs group F, P ,0.001. 2134 gd1 Inhibitory Cells in TCRa2/2 Mice
The three resultant populations of TCRa2/2 cells were
then individually incubated with 129/J immune CS-effec-
tor cells for 30 min at 378C, and each mixture of cells was
subsequently assayed for CS-effector function after transfer
to naive recipients. The results in Fig. 6 a demonstrate once
more that TNBSA-treated TCRa2/2 mice are a reliable
source of downregulation of CS-effectors (group B), and
that this activity is unaffected by treatment with either anti-
CD4 (group C), or anti-CD8 (group D). Results are con-
sistent with the active regulators being double negative
(DN)  gd T cells.
DN gd T cells have been reported in the lymphoid sys-
tem of essentially all vertebrates examined, but they occur
in mice in very low numbers relative to ab T cells. There-
fore, to assess the potency of DN gd T cells to downregu-
late CS, a dose–response experiment was performed. 10-
fold dilutions (2.5 3 105, 2.5 3 104, or 2.5 3 103) of 60%
gd TCR1 cells (purified from TNBSA-tolerized a2/2
mice by use of magnetic beads) were incubated, each with
Figure 4. (a) Reciprocal Ag specificity of
splenic gd1 regulatory cells from TNP or
OX-tolerized a2/2 mice that act on TNP
versus OX-immune CS-effector T cells.
BDF1 mice were used as donors and recipi-
ents of PCl or OX immune cells, while
their H2b,d TCRa2/2 counterparts were
used as donors of tolerized regulatory cells.
To tolerize spleens of TCRa2/2 mice, nor-
mal a2/2 spleen cells were conjugated in
vitro with TNP or OX, and 5 3 107 hap-
ten-conjugated self cells were injected intra-
venously into a2/2 mice on days 0 and 3,
and then spleen cell suspensions from these
tolerized recipients were prepared on day 7
as putative regulatory cells. BDF1 CS-effec-
tor cell donors were contact skin-sensitized
with TNP (via PCl painting) (groups A–C),
or with OX (groups D–F), on days 0 and 3,
and then spleen and lymph node cells were
transferred into BDF1 recipients on day 7,
either alone (7 3 107 cells) (groups A and
D), or mixed with Ag homologous down-
regulatory a2/2 cells (groups C and E), or
Ag heterologous downregulatory cells (5 3
107) from TCRa2/2 mice (groups B and F).
Adoptive cell recipients that were MHC
homologous to CS-effector cells that were
cotransferred, were challenged on the ears
with TNP or OX hapten, and ear swelling
measurements were made 24 h later. Each
group consisted of three mice. Statistical sig-
nificance: group A vs C, P ,0.001; and
group  D vs E, P , 0.002; group D vs F NS.
(b) Antigen-specificity of tolerance in a2/2
mice tested as recipients of a1/1 CS-effec-
tor cells. To confirm Ag-specificity of toler-
ized a2/2 mice we used an assay that did
not involve transfers and manipulation of the putative regulatory cells. a2/2 mice were tolerized by intravenously injection of TNBSA or OX-MRBC
before serving as recipients for transfer of CS-effector cells from normal BALB/c mice that were of homologous or unrelated Ag (TNP vs OX) specific-
ity. The experiments included groups of positive and negative controls. Mice were then challenged immediately on the ears with homologous hapten
(TNP or OX), and then tested for CS ear swelling 24 and 48 h later. Statistical analysis at 24 h using the two tailed Student’s t test showed: group B vs A,
P ,0.01; group B vs C, P ,0.02; group E vs D, P ,0.01; group E vs F, P ,0.01. For 48 h: group B vs A, P ,0.02; group B vs C, P ,0.01; group E
vs D, P ,0.001; and group E vs F, P ,0.01.
Figure 5. Lack of MHC restriction of gd downregulatory cells from
TNBSA-tolerized TCRa2/2 mice. Magnetic bead positive (gd TCR1)
cells from TNBSA-tolerized a2/2 mice were incubated with 7 x 107 cells
from MHC compatible 129/J H2b,d, or MHC incompatible (CBA/J,
H2k) mice for 30 min at 378C (groups B and D). As a positive control, we
used immune cells from 129/J or CBA/J mice that were incubated with-
out regulatory cells in medium alone (groups A and C). Then cells were
washed and injected intraperitoneally into recipients that were syngeneic
with the immune cells, and were skin tested for CS responsiveness. Statis-
tical significance: group A vs B, and group C vs D, P ,0.001.2135 Szczepanik et al.
7 3 107 PCl-immune CS-effector 129/J cells for 30 min at
378C, and then were harvested, washed, and transferred.
Recipient ear swelling results (Fig. 6 b) showed a strong
dose response of the assay to the inocula (groups B–D).
Even the dose of 2.5 3 103 gd T cells had activity in the
assay (group D), albeit weaker than the other doses. The
capacity of very small numbers of downregulatory gd T
cells to score in this bio-assay is discussed below.
gd Cells From TNBSA-tolerized TCRa2/2 Mice Inhibit In
Vitro Production of IFN-g by TNP-specific CS–effector T
Cells. Since IFN-g is a central cytokine in Th-1–medi-
ated responses, such as DTH and CS, we determined
whether IFN-g production by CS-effector TNP-immune
cells was affected by regulatory cells induced by high dose
intravenous TNBSA or OX tolerogenesis. Using two dif-
ferent anti–IFN-g antibodies in an ELISA assay, it was first
established that 2 3 105 lymph node cells from contact im-
munized mice, stimulated in vitro by TNP-conjugated
APC, secreted .3 ng/ml IFN-g over a 48 h period. Com-
pared to production of IFN-g by CS-effector cells mixed
with nonimmune spleen cells (Fig. 7 a, groups A and D),
IFN-g production by CS-effector cells and TNP-APC was
substantially inhibited by mixing with spleen cells from in-
travenous TNBSA tolerized normal a1/1 mice (Fig. 7 a,
group B) and also with spleen cells from intravenous TNBSA
tolerized a2/2 mice (Fig. 7 a, group E). Also, as controls,
spleen cells from nonimmune and nontolerized animals in-
cubated alone or in the presence of TNP or OX-APC did
not secrete detectable levels (0.1 ng) of IFN-g (data not
shown).
To determine the phenotype of regulatory cells responsi-
ble for the in vitro suppression of IFN-g production, gd
TCR1 or gd TCR2 cells in the spleens were separated, us-
ing anti-gd antibody coated magnetic beads that were used
to separate spleen cells from nontolerized, TNBSA-toler-
ized, or OX-tolerized TCRa1/1 or TCRa2/2 mice, and
then equivalent numbers of each cell subpopulation were
added to TNP-immune CS–effector cells in vitro, and cul-
tured together with TNP-hapten–conjugated APC. There
was a striking suppression of IFN-g production by gd1
cells from TNBSA-tolerized a2/2 mice (Fig. 7 b, group E,
left) that did not occur with gd1 cells from TNBSA-toler-
ized a1/1 mice (Fig. 7 b, group B, left). In contrast, the in-
hibitory activity of TNBSA-tolerized a1/1 mice was shown
to be due to gd2 cells (Fig. 7 b, group B, right), and thus
was probably due to ab T cells. In contrast to the down-
regulatory activity of gd1 cells from TNBSA-tolerized a2/2
mice, the gd2 cells of these mice were totally without in-
hibitory activity (Fig. 7 b, group E, right), as were OX-tol-
erized gd1 and gd2 cells (Fig. 7 b, group C and F, left),
again varifying Ag-specificity of gd1 cells mediating toler-
ance.
These in vitro findings were consistent with the in vivo
findings. Thus, we concluded that suppressive cells in Ag-
tolerized a2/2 mice were potent Ag-specific gd downreg-
ulatory T cells, both in vivo with contact sensitivity, and in
vitro with IFN-g production, while T cells that inhibited
CS in vivo and IFN-g in vitro that were obtained from
normal a1/1 mice, were not gd T cells, and probably were
ab T cells. The failure of most cell mixtures tested in Fig. 7 b
to reduce IFN-g production demonstrated that selected re-
ductions in IFN-g production were not readily attributable
to nonspecific effects of extra cells in the assay, such as
binding of IFN-g to IFN-g receptors, or to degradation of
secreted IFN-g.
Discussion
ab T cell–deficient mice do not elicit the classical 24 h
component of CS after active contact sensitization and sub-
sequent skin challenge. This result extends previous find-
ings implicating ab T cells as principal effectors in CS re-
sponses (7, 8, 25, 26): i.e., ab T cells and gd T cells are not
redundant in their functional capacity as effector cells in
CS. By contrast, TCRa2/2 mice can respond to high dose
Ag tolerance by the induction of cells that can downregu-
late CS-effector activity from a1/1 immunized donors.
Figure 6. Phenotype (a) and dose response of gd downregulatory cells
derived from TNBSA-tolerized a2/2 mice (b). (a) Phenotype: To deter-
mine phenotype of downregulatory cells, spleen cells from TNBSA-toler-
ized a2/2 mice were incubated with medium alone, or with mAb (anti-
CD4 or anti-CD8) for 40 min on ice. Cells were washed and incubated
with rabbit complement for 45 min at 378C, and were washed and resus-
pended in PBS. 7 3 107 CS-effector cells were incubated with medium
alone (group A, positive control), with 5 3 107 untreated tolerized cells
(group B), or with 5 3 107 anti-CD4 1 C treated tolerized cells, (group
C), or with 5 3 107 anti-CD8 1 C treated tolerized cells, (group D). Sta-
tistical significance: group A vs B, and group A vs C P ,0.001, and group
A vs D P ,0.01. (b)-Dose response: 7 3 107 immune CS effector cells
were incubated with medium alone (group A, positive controls), or with
10-fold decreasing dilutions (2.5 3 105, 2.5 3 104, or 2.5 3 103 cells) of
magnetic bead positive (gd TCR1) downregulatory cells from a2/2 TN-
BSA-tolerized mice, for 30 min at 378C (groups B–D). After incuba-
tion, the cell mixtures were washed and injected into recipients that were
challenged on the ears, and measured for CS responses at 24 h. Statistical
significance: group A vs B and C, P ,0.001, group A vs D, P ,0.01.2136 gd1 Inhibitory Cells in TCRa2/2 Mice
This was shown in two ways: splenocytes from tolerized
TCRa2/2 mice downregulate CS-effector cells with which
they are mixed in vitro, before cotransfer and elicitation of
CS, and high dose Ag-treated tolerized TCRa2/2 mice in-
hibit the transfer of CS-effectors that function normally in
untreated TCRa2/2 mice.
The experiments presented here demonstrate that gd cell–
enriched fractions from TCRa2/2 mice are better media-
tors of high dose Ag tolerance than are gd cell–depleted
fractions, suggesting that gd T cells are the active regulatory
cells, as opposed to TCRb1a2 cells that are a potential fea-
ture of TCRa2/2 mice (27–28). The lack of conventional
MHC restriction shown by the TCRa2/2 regulatory cells,
and their CD42CD82 phenotype are both consistent with
most assays of gd function (29). The apparent hapten spec-
ificity of the regulatory gd cells demonstrated herein for
the first time may be considered consistent with the hy-
pothesis that the potential diversity (30) of the gd TCR
is greater than that of any other Ag receptor (31). Thus,
overall, downregulation can be mediated by Ag-specific gd
T cells, and need not be solely mediated by specific ab
T cells. However, in this study we have provided no evi-
dence that the gd cells directly recognized either PCl/TNP
or OX, nor whether the gd cells recognized either conven-
tional APCs, or the effector T cells with which they were
mixed, or some other cells. Conceivably all of these cells
may have been haptenated.
Commonly, it has been argued that TCRa2/2 mice are
deficient in immune effector responses because ab cells are
uniquely capable of specifically responding to the challeng-
ing antigen. However, the apparent capacity of gd cells in
TCRa2/2 mice to distinguish between CS-effector cells
that are responsive to different hapten Ag raises questions
about the completeness and/or validity of this explanation.
Possibly, potential gd effector cells responsive to challenge
by specific Ag may be unable to mount strong immune ef-
fector responses because they cannot interact efficiently
with the professional antigen presenting cell system. This
may be for physiologic reasons; e.g., gd cells may occur in
an inappropriate anatomical location, in insufficient num-
Figure 7. (a) gd T cells in
spleens of TNBSA intravenously
tolerized a2/2 mice Ag-specifi-
cally downregulate IFN-g pro-
duction by CS-effector T cells.
2  3 105 TNP-immune CS-effec-
tor cells from a1/1 mice were
cultured in vitro in the presence
of TNP-conjugated normal
spleen cells as APC, either with
or without added regulatory cells
(group  A), or with regulatory
cells of two different specificities:
either TNBSA-tolerized or OX-
tolerized. These regulatory cells
were either from a1/1 normal
mice (groups B and C), or were
harvested from TNBSA-toler-
ized or OX-tolerized a2/2 mice
(groups E and F, respectively).
At the end of 48 h, supernatants
from the individual microwell
cultures were harvested and as-
sayed subsequently for IFN-g
content with a double mAb cap-
ture ELISA immunoassay. Statis-
tics: group A vs B, P ,0.004;
group  C vs A, P ,0.01; group E
vs D, P ,0.004; and group F vs
D, P ,0.02. (b) Phenotype of in
vitro gd down regulatory cells:
2  3 105 lymph node CS-effector
cells from PCl-sensitized donors
were cultured in individual wells
of flat-bottomed wells of mi-
crotrays in quadruplicate with
TNP- or OX-conjugated synge-
neic spleen cells as APC, either alone (groups A and D), or with regulatory cell subpopulations from TNBSA-tolerized or OX-tolerized donors (group
B and groups C, E, and F). These regulatory cells came from either normal a1/1 mice (groups B and C), or from matched TCRa knockout a2/2 mice.
Prior to addition to microcultures, these regulatory cells were each separated by immunomagnetic bead techniques, using anti-gd TCR mAb, into gd-
enriched cells (gd1, left), or gd-depleted cells (gd2, right). After 48 h culture of the various cell mixtures, supernatants were harvested from individual
wells and assayed subsequently using a two mAb capture ELISA immunoassay for IFN-g content. Statistics: group A vs B (left), NS; group A vs B (right),
P ,0.001; group A vs C (right), P ,0.001; group D vs E (left), P ,0.002; group D vs F (left), NS; group D vs E (right), NS.2137 Szczepanik et al.
bers, or produce inappropriate effector molecules. How-
ever, equally attractive is the idea that gd cells, like B cells,
only rarely recognize molecular complexes of antigenic
peptides and MHC. In such a case, gd cells would not
“learn” that the body was infected from APCs and could
not be expected to mount a conventional immune re-
sponse of the kind that we associate with APC-ab T cell
interactions (31).
Provocatively, the data presented here bear striking simi-
larities with the role of gd cells reported in another system,
namely the IgE allergic responsiveness of mice to protein
antigen aerosols (18, 19). Thus gd T cells reduced ovalbu-
min-specific IgE responses in rats and mice that were toler-
ized with ovalbumin administered via repetitive respiratory
aerosol administration (18, 19). Not only were gd T cells
shown to be active in both cases, but strikingly low num-
bers of gd T cells per animal (z2 3 103) were effective, as
also was the case here (Fig. 6 b). Likewise, systemic oral tol-
erance to ovalbumin was suggested to be due to gd T cells
(32). Recently it was also shown that mice deficient in gd
T cells, and responding to infection with a natural intestinal
pathogen, Eimeria, had exaggerated gut immunopathology
attributable to unrestrained ab T cell function, or the ef-
fects thereof, suggesting a downregulatory function of gd
T cells (33). In other studies, gd T cells from T. cruzi in-
fected mice were shown to be suppressive in vivo and in
vitro, correlating with autoimmunity (34). Finally, hepatic
gd T cells could adoptively transfer tolerance to allogeneic
skin grafts, and also reduced lymphokine production (35).
gd T cells in tumor bearing mice were reported to decrease
anti-tumor cytotoxic T cell activity (36). Thus, the data
presented here, in the classical CS system, provide a clear
demonstration of a fundamental functional phenotype of
gd cells that is operative in numerous systems, including al-
lergy to aerosolized antigen, oral tolerance, autoimmunity,
transplantation, tumor immunity, and pathogenesis of in-
fectious diseases. As such, the downregulation of ab T cells
by the effects of gd T cells is emerging as a major and prob-
ably general functional capacity.
The downregulatory effect of gd T cells that we describe
may in part be effected by a direct or indirect inhibition of
IFNg production by the CS-effector cells, as our results
suggest. The mechanism for this inhibition has yet to be re-
solved. An obvious possibility is the production by gd T cells
of cytokines that inhibit T cell production of IFN-g, such
as TGFb, IL-4, or IL-10. The production by gd T cells of
IL-4 would be consistent with the capacity of gd T cells
from TCRa2/2 mice to support copious production of an-
tibodies (22). Thus, regulation of CS by gd T cells may be
another instance of Th2 regulation or diversion of Th1
cells (37). Alternatively, gd T cells may regulate CS-effec-
tor ab T cells by their being eliminated via injury, apopto-
sis, or cytotoxic lysis. There are many reports that gd T cells
possess cytotoxic activity (38, 39). However, it is notewor-
thy that we have recent evidence that in vitro tolerance for
IFN-g production by splenocytes of TNBSA-tolerized
mice can be reversed by IL-12 (Ushio, H., and P.W. Aske-
nase, unpublished results), suggesting that cytotoxicity may
not be the mechanism for gd T cell-mediated TNBSA tol-
erance.
In summary, DTH and CS are examples of important in
vivo Th1 responses that can play a crucial role in defense
against diverse microbial pathogens and tumor cells, and as
effectors of some allergic and autoimmune diseases. This
may be the reason for such tight regulation of these re-
sponses. It is possible that changes in immunoregulation
could be a cause for decreased immune resistance in serious
infections, or in cancers, or perhaps for the abnormally in-
creased immune responses that occur in allergies and au-
toimmunity. The findings of the current study clearly es-
tablish that gd T cells can function as a newly recognized
component of immune downregulation, and may be able
to do so in an Ag-specific fashion, the underlying mecha-
nism of which needs now to be defined.
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